The effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia.
Adult
Antipsychotic Agents
/ administration & dosage
Attention
/ drug effects
Cognitive Dysfunction
/ drug therapy
Executive Function
/ drug effects
Eye Movement Measurements
Female
Follow-Up Studies
Humans
Lurasidone Hydrochloride
/ administration & dosage
Male
Memory, Short-Term
/ drug effects
Middle Aged
Outcome Assessment, Health Care
Saccades
/ drug effects
Schizophrenia
/ complications
Spatial Memory
/ drug effects
Executive control
Eye movement
Treatment-resistant schizophrenia
Working memory
Journal
Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
05
07
2019
revised:
30
09
2019
accepted:
06
10
2019
pubmed:
11
11
2019
medline:
20
1
2021
entrez:
11
11
2019
Statut:
ppublish
Résumé
Eye movement (EM) measures can serve as biomarkers to evaluate pharmacological effects on brain systems involved in cognition. In recent onset schizophrenia, antipsychotic treatment can improve attentional control on the antisaccade task and exacerbate working memory impairment on the memory guided saccade task; effects in treatment-resistant schizophrenia (TRS) are less clear. This study evaluated the effects of high versus low dose lurasidone on EM performance in TRS. TRS patients completed EM testing: 1) at baseline, on existing medication regimen (n = 42), 2) after 6 weeks of low dose (80 mg) lurasidone (n = 38), 3) after 12 weeks following randomization to low (80 mg) or high dose (240 mg) lurasidone (n = 27), and 4) after 24 weeks of treatment (n = 23). EM testing included prosaccade, antisaccade, and memory guided saccade tasks. Six weeks of lurasidone resulted in increased prosaccade saccade latency and reduced antisaccade errors, with no change in memory guided saccade accuracy. After randomization, prosaccade and antisaccade latencies increased in only the high dose group, with no change in antisaccade errors in both groups. Memory guided saccade error increased in the high dose group and remained stable in the low dose group. Among TRS, stabilization on low dose lurasidone was associated with improved executive control of attention reflected by reduced antisaccade errors. High dose lurasidone resulted in prolonged speed of reflexive and executive shifts of attention and reduced spatial working memory relative to low dose. These findings indicate that EM measures are helpful biomarkers of dose-dependent antipsychotic treatment effects on executive cognitive abilities in TRS.
Identifiants
pubmed: 31706786
pii: S0920-9964(19)30439-6
doi: 10.1016/j.schres.2019.10.008
pii:
doi:
Substances chimiques
Antipsychotic Agents
0
Lurasidone Hydrochloride
O0P4I5851I
Banques de données
ClinicalTrials.gov
['NCT01569659']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
314-321Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Herbert Meltzer receives, or has received, other grant support from ACADIA, Allergan, Dainippon Sumitomo, Sunovion, Eli Lilly, Janssen, Lundbeck, Neurocrine, and Reviva. He also receives support from the Weisman Family Foundation. None of the other authors have potential conflicts of interest.